Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.

Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians at more than 360 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune to newly diagnosed and recurrent glioblastoma (GBM) patients. Physicians at an additional 140 medical institutions throughout the world also can prescribe …

FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today that the RTOG Foundation will conduct a phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM). The RTOG Foundation recently received an investigational …

OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets

April 15, 2016 08:46 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024” report to their offering. Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival …

Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016

New Findings Show TTFields May Be Optimized to Prevent Migration and Invasion of Glioma Cells ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) will present three preclinical abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held April 16-20 in New Orleans. The abstracts highlight the latest understanding of the mechanism of …

Novocure to Report First Quarter 2016 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its first quarter 2016 financial results at 5 p.m. EDT on Monday, May 9, 2016. Schedule for press release and conference call: Q1 press release: After market close on May 9, 2016 Q1 conference call/webcast: 5 p.m. EDT on May …